Montara Therapeutics, Inc., a San Francisco, CA-based therapeutics firm aiming to advance brain-targeting medicine, closed an $8m seed financing.
The spherical was led by SV Well being Traders’ Dementia Discovery Fund and co-lead Two Bear Capital. Dolby Household Ventures and KdT Ventures additionally participated within the spherical. In reference to this financing, Dirk Landgraf, Ph.D., Principal at SV, and J. Seth Strattan, Ph.D., Common Accomplice at Two Bear Capital, have joined Montara’s Board of Administrators.
The corporate intends to make use of the funds to advance its common peripheral blocker and a neurological disease-targeting drug with confirmed scientific profit however extreme dose-limiting peripheral unwanted effects. Montara has additionally initiated chemistry on subsequent applications for Alzheimer’s and Parkinson’s illness.
Led by Nicholas T. Hertz, Ph.D., Founder and Chief Govt Officer, Montara Therapeutics is a preclinical-stage biopharmaceutical firm pursuing novel approaches to develop safer and extra efficacious remedies for neurological ailments. Its BrainOnly platform permits brain-specific pharmacology using present and novel chemical warheads, proscribing deleterious on-target off-tissue peripheral exercise.
The platform relies on analysis from the Shokat Lab at The College of California, San Francisco (UCSF), and was revealed in Nature in 2022 (link to paper). The know-how is solely licensed from UCSF via its Workplace of Know-how Administration and Development.
Montara was based in 2023 by Nicholas T. Hertz, Ph.D., and scientific co-founders: UCSF Professor Kevan Shokat, Ph.D., who invented the covalent inhibition strategy to focus on KRAS G12C, a beforehand undruggable goal, and co-founded many profitable biotechnology firms; Stanford College Professor Thomas Südhof, M.D., who received the Nobel Prize for his analysis in vesicle trafficking; and UCSF Professor Martin Kampmann, Ph.D., who has carried out in depth analysis in aging-associated neurodegenerative ailments. The entire scientific co-founders will serve on Montara’s Scientific Advisory Board. For the reason that firm’s founding, the Dementia Discovery Fund has intently collaborated with Dr. Hertz on the marketing strategy and the company and pipeline technique.
Previous to founding Montara, Drs. Hertz and Shokat collaborated to discovered Mitokinin, which superior a possible first-in-class disease-modifying remedy for Parkinson’s illness. In October 2023, Mitokinin was acquired by AbbVie for $110 million upfront and as much as $655 million in complete deal worth, along with tiered royalties.
FinSMEs
30/07/2024
